Dabigatran
Drug Category | Drug | IHD Dosing | Administration Timing Around HD Session |
---|---|---|---|
Cardiovascular Medications (Misc.) | Dabigatran | Not Recommended | Not Recommended |
Molecular Weight (Da) | Excreted Unchanged (%) | Normal Half-Life (Hours) | ESRD Half-Life (Hours) | Plasma Protein Binding (%) | Volume of Distribution (L/kg) | Dialytic Plasma Clearance (ml/min) | % Dialyzed |
---|---|---|---|---|---|---|---|
472 | 80 | 12-17 | 28 | 35 | 0.7-1 (based on 70 kg) | N/A | 68 (N/A) |
References:
- DrugBank [Online]. 2012 Apr 12 [cited 2012 May 6]; Available from: URL: http://www.drugbank.ca/drugs/DB06695
- Stangier J, Rathgen K, Sta H. Influence of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Oral Dabigatran Etexilate. Clinical pharmacokinetics. 2010;49(4):259-268.